期刊
LANCET
卷 375, 期 9715, 页码 641-648出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(09)61921-8
关键词
-
资金
- National Cancer Institute (Bethesda, MD, USA) [5U10 CA11488-32, 5U10 CA011488-38]
- EORTC Charitable Trust
- UK National Health Service
- MRC [E164/52] Funding Source: UKRI
- Medical Research Council [E164/52] Funding Source: researchfish
Background In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a. Methods RE04/30012 was an open-label randomised trial undertaken in 50 centres across eight countries. 1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non-stratified log-rank test. Analysis was by intention to treat. This study is registered, number ISRCTN 46518965. Findings 502 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment. Median follow-up was 37.2 months (24.8-52.3). Median overall survival was 18.8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for those receiving combination therapy. overall survival did not differ between the two groups (hazard ratio 1.05 [95% Cl 0.90-1.21], p=0.55; absolute difference 0.3% (-5.1. to 5.6) at 1 year and 2.7% (-8.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving combined treatment. Interpretation Although combination therapy does not improve overall or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have a role because it can produce remissions that are of clinically relevant length in some patients. identification of patients who will benefit from immunotherapy is crucial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据